Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine

Abstract The number of polymorphisms identified in genes encoding drug metabolising enzymes, drug transporters, and receptors is rapidly increasing. In many cases, these genetic factors have a major impact on the pharmacokinetics and pharmacodynamics of a particular drug and thereby influence the sensitivity to such drug in an individual patient with a certain genotype. The highest impact is seen for drugs with a narrow therapeutic index, with important examples emerging from treatment with antidepressants, oral anticoagulants, and cytostatics, which are metabolised by the polymorphic enzymes cytochrome P450 2D6 (CYP2D6), cytochrome P450 2C9 (CYP2C9), and thiopurine-S-methyltransferase (TPMT), respectively. In order to apply the increasing amount of pharmacogenetic knowledge to clinical practise, specific dosage recommendations based on genotypes will have to be developed to guide the clinician, and these recommendations will have to be evaluated in prospective clinical studies. Such development will lead to a patient-tailored drug therapy which hopefully would be more efficient and will result in fewer adverse drug reactions.

[1]  L. Bertilsson,et al.  Pharmacogenetics of Drug Metabolism: Two Clinically Important Polymorphic Enzymes, CYP2D6 and TPMT , 2005 .

[2]  M. Eichelbaum,et al.  Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.

[3]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[4]  J. Goldstein,et al.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.

[5]  M. Kennedy,et al.  Beta-adrenergic receptor polymorphisms and drug responses in asthma. , 2002, Pharmacogenomics.

[6]  M. Ratain,et al.  Update on pharmacogenetics in cancer chemotherapy. , 2002, European journal of cancer.

[7]  H. McLeod,et al.  The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. , 2002, Pharmacogenomics.

[8]  M. Dahl.  Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics , 2002, Clinical pharmacokinetics.

[9]  J. Goldstein,et al.  Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. , 2001, Pharmacogenetics.

[10]  M. Ingelman-Sundberg,et al.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. , 2001, British journal of clinical pharmacology.

[11]  S. Kasper,et al.  CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages , 2001, Acta psychiatrica Scandinavica.

[12]  R. Kim,et al.  Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.

[13]  S. Leucht,et al.  Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[14]  K. Chiba,et al.  Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. , 2001, British journal of clinical pharmacology.

[15]  M. Relling,et al.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Ratain,et al.  Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[17]  U. Brinkmann,et al.  ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. , 2001, Pharmacogenomics.

[18]  D. Collier,et al.  Pharmacogenetics for the Individualization of Psychiatric Treatment , 2001, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[19]  M. Margaglione,et al.  Genetic Modulation of Oral Anticoagulation with Warfarin , 2000, Thrombosis and Haemostasis.

[20]  W. Evans,et al.  Genetic Polymorphism of Thiopurine S-Methyltransferase: Molecular Mechanisms and Clinical Importance , 2000, Pharmacology.

[21]  E. Nanba,et al.  Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. , 2000, Pharmacogenetics.

[22]  T. Baglin,et al.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. , 2000, Blood.

[23]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[24]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[25]  S. Preskorn,et al.  Therapeutic Drug Monitoring of Antidepressants , 1999 .

[26]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[27]  A. Brookes.  The essence of SNPs. , 1999, Gene.

[28]  M. Relling,et al.  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. , 1999, Blood.

[29]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[30]  M. Ingelman-Sundberg,et al.  Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. , 1999, Gene.

[31]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[32]  M. Eichelbaum,et al.  Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. , 1998, Pharmacogenetics.

[33]  M Ingelman-Sundberg,et al.  A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. , 1997, Molecular pharmacology.

[34]  I. Lewis,et al.  Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies. , 1997, Medical and pediatric oncology.

[35]  W. Trager,et al.  Genetic association between sensitivity to warfarin and expression of CYP2C9*3. , 1997, Pharmacogenetics.

[36]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[37]  J. Brockmöller,et al.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.

[38]  L. Kaminsky,et al.  Human P450 metabolism of warfarin. , 1997, Pharmacology & therapeutics.

[39]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[40]  M. Ingelman-Sundberg,et al.  A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. , 2003, British journal of clinical pharmacology.

[41]  R. Blouin,et al.  The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry , 1996, Clinical pharmacology and therapeutics.

[42]  R. Weinshilboum,et al.  Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. , 1996, DNA and cell biology.

[43]  M. Relling,et al.  A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Ingelman-Sundberg,et al.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.

[45]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[46]  E. Pantuck.  Plasma Cholinesterase: Gene and Variations , 1993, Anesthesia and analgesia.

[47]  J. Gummert,et al.  Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient , 1993, The Lancet.

[48]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[49]  E. Beutler.  Study of glucose‐6‐phosphate dehydrogenase: History and molecular biology , 1993, American journal of hematology.

[50]  U A Meyer,et al.  Genotype or phenotype: the definition of a pharmacogenetic polymorphism. , 1991, Pharmacogenetics.

[51]  M. Eichelbaum,et al.  Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.

[52]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[53]  R. Weinshilboum,et al.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.

[54]  R. Skoda,et al.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. , 1989, American journal of human genetics.

[55]  R. Skoda,et al.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[56]  D. Nebert,et al.  Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. , 1988, Genomics.

[57]  L. Bertilsson,et al.  Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. , 1985, Therapeutic drug monitoring.

[58]  L. Bertilsson,et al.  Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. , 1980, Life sciences.

[59]  R. Weinshilboum,et al.  Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. , 1978, Clinica chimica acta; international journal of clinical chemistry.

[60]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[61]  F. Sjöqvist,et al.  Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. , 1967, Life sciences.

[62]  F. Vogel.  Moderne Probleme der Humangenetik , 1959 .

[63]  W. Kalow,et al.  A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers. , 1973, Canadian journal of biochemistry and physiology.

[64]  W. Kalow,et al.  A METHOD FOR THE DETECTION OF ATYPICAL FORMS OF HUMAN SERUM CHOLINESTERASE. DETERMINATION OF DIBUCAINE NUMBERS , 1957 .

[65]  H. Bernstein,et al.  INTERNAL ROTATION: IX. THE INFRARED AND RAMAN SPECTRA OF LIQUID NORMAL ALKYL BROMIDES , 1957 .

[66]  L. H. Schmidt,et al.  Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. , 1954, American review of tuberculosis.